# Biomea Fusion, Inc.: overview BMEA · Nasdaq · CIK 1840439 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bmea.md) · [Financials](/companies/bmea/financials.md) · [Filings](/companies/bmea/filings.md) · [Insiders](/companies/bmea/insiders.md) Latest reported revenue: [$165.0m](/filings/0000950170-22-022607.md) for Q3 FY2022, three months to 2022-09-30, from the 10-Q filed Nov 7, 2022 (XBRL us-gaap:Revenues, accession 0000950170-22-022607). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.91)](/filings/0001193125-25-264679.md) | [(0.81)](/filings/0000950170-25-047775.md) | [(0.80)](/filings/0001193125-26-217074.md) | [(0.51)](/filings/0001193125-26-335085.md) | [(0.27)](/filings/0001193125-25-264679.md) | not reported | [(0.17)](/filings/0001193125-26-217074.md) | [(0.12)](/filings/0001193125-26-335085.md) | | Free cash flow | $m | [(25.4) d](/filings/0001193125-25-264679.md) | [(30.1) d](/filings/0001193125-26-121825.md) | [(25.7)](/filings/0001193125-26-217074.md) | [(19.2) d](/filings/0001193125-26-335085.md) | [(11.6) d](/filings/0001193125-25-264679.md) | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.74)](/filings/0000950170-24-038026.md) | [(2.80)](/filings/0000950170-25-047775.md) | [(3.44)](/filings/0001193125-26-121825.md) | [(3.83)](/filings/0001193125-26-121825.md) | [(1.18)](/filings/0001193125-26-121825.md) | | Free cash flow | $m | [(38.6)](/filings/0000950170-24-038026.md) | [(63.4)](/filings/0000950170-25-047775.md) | [(100.0)](/filings/0001193125-26-121825.md) | [(120)](/filings/0001193125-26-121825.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bmea/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $13.0m | 8,814,946 | | Added +1,587 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.2m | 2,829,927 | | Added +232,627 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $3.0m | 2,049,802 | | Added +851,251 | | [Aisling Capital Management LP](/funds/1766721.md) | 2026-06-30 | $3.0m | 2,048,757 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $2.1m | 1,455,474 | | Added +142,676 | | [FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A.](/funds/1280487.md) | 2026-06-30 | $1.1m | 723,176 | | Added +166,140 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.1m | 715,445 | | Added +74,010 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.0m | 708,854 | | Added +160,668 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $900.7k | 612,735 | | Reduced −17,130 | | [Mariner, LLC](/funds/1373442.md) | 2026-06-30 | $874.2k | 594,726 | | Reduced −59,852 | ## Recent filings [All 287 filings](/companies/bmea/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-14 | 21:35 ET | [8-K](/filings/0001193125-26-420684.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-420684 | | 2026-09-22 | 20:01 ET | [8-K](/filings/0001193125-26-397870.md) | 8.01 Other events | 0001193125-26-397870 | | 2026-08-05 | 20:09 ET | [10-Q](/filings/0001193125-26-335085.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335085 | | 2026-08-05 | 20:07 ET | [8-K](/filings/0001193125-26-335073.md) | 9.01 Financial statements and exhibits | 0001193125-26-335073 | | 2026-06-11 | 11:11 ET | [8-K](/filings/0001193125-26-266687.md) | 5.07 Shareholder vote results | 0001193125-26-266687 | | 2026-05-11 | 21:01 ET | [10-Q](/filings/0001193125-26-217074.md) | Quarterly report, period 2026-03-31 | 0001193125-26-217074 | | 2026-05-11 | 20:58 ET | [8-K](/filings/0001193125-26-217037.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-217037 | | 2026-04-28 | 12:30 ET | [8-K](/filings/0001193125-26-183710.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-183710 | | 2026-04-27 | 20:08 ET | [DEF 14A](/filings/0001193125-26-182080.md) | Proxy statement, period 2026-06-10 | 0001193125-26-182080 | | 2026-03-24 | 20:12 ET | [10-K](/filings/0001193125-26-121825.md) | Annual report, period 2025-12-31 | 0001193125-26-121825 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-121825.md), filed Mar 24, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1840439 - Tickers: BMEA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.